TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, the association of the TGF-β inhibitors, Ly364947 with Imatinib [47] or EW-7197 with Imatinib, Dasatinib or Ponatinib [11] was efficient to respectively decrease the maintenance of LSCs and to eliminate CML leukemia-initiating cells.